Navigation Links
Venaxis' APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
Date:7/15/2013

atements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Prospectus filed on May 24, 2013.

For Investors and Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, PhD
jdrumm@tiberend.com; (212) 375-2664
Clair
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Venaxis Announces Pricing of Offering of Common Stock and Warrants
2. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
3. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
4. Eastern Clinical Trials Russia CRO Passes EMA Inspection
5. Legendary Author And Screenwriter Nora Ephron Passes Away At 71; Solar Cigarette Pays Tribute To Such A Rare Talent
6. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
7. Free Expo-Hall Passes for ATA 2012
8. Accuray Surpasses 600 Installations Globally
9. Unisense FertiliTech to Present Large Scale Time-lapse Data Analysis to Improve IVF Treatment
10. New Approaches in Immunogenicity Assessment Using the New SQiDlite™ System: Case Study Analysis, New Life Science Webinar Hosted by Xtalks
11. Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/20/2014)... Mapp Biopharmaceutical,s valiant effort to produce ... fight the Ebola outbreak will make the public ... of pharmaceuticals can be, according to Kalorama Information.  ... some may be taken aback by the three-month ... knowledge are well aware of the complex issues ...
(Date:10/20/2014)... -- , A major pan-European survey into ... of care has revealed changing trends in many important ... provision of healthcare services across the continent. The results ... Gastroenterology (UEG), have been announced today and led to ... burden of GI disorders across Europe ...
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Standards and Technology (NIST) colored lots of eggs recently. ... smallin fact, too small to see without a microscope. ... strategies for making future low-power computer memories. For ... used electron-beam lithography to make thousands of nickel-iron magnets, ...
... new kind of cloaking material that can render ... this design can,t translate into an invisibility cloak ... in diagnostics, security, and communication. The cloak, ... engineering at Northwestern,s McCormick School of Engineering and ...
... 27, 2011 Talecris Biotherapeutics Holdings Corp. ("Talecris") (NASDAQ: ... for the three months ended March 31, 2011 and ... Exchange Commission (SEC). First quarter 2011 net ... million from $381.0 million in the first quarter of ...
Cached Biology Technology:Good eggs: NIST nanomagnets offer food for thought about computer memories 2Researchers create terahertz invisibility cloak 2Talecris Biotherapeutics Announces First Quarter 2011 Results 2Talecris Biotherapeutics Announces First Quarter 2011 Results 3Talecris Biotherapeutics Announces First Quarter 2011 Results 4Talecris Biotherapeutics Announces First Quarter 2011 Results 5Talecris Biotherapeutics Announces First Quarter 2011 Results 6Talecris Biotherapeutics Announces First Quarter 2011 Results 7Talecris Biotherapeutics Announces First Quarter 2011 Results 8Talecris Biotherapeutics Announces First Quarter 2011 Results 9Talecris Biotherapeutics Announces First Quarter 2011 Results 10Talecris Biotherapeutics Announces First Quarter 2011 Results 11Talecris Biotherapeutics Announces First Quarter 2011 Results 12Talecris Biotherapeutics Announces First Quarter 2011 Results 13Talecris Biotherapeutics Announces First Quarter 2011 Results 14Talecris Biotherapeutics Announces First Quarter 2011 Results 15Talecris Biotherapeutics Announces First Quarter 2011 Results 16
(Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
(Date:10/18/2014)... a group of 2,000 patients referred for evaluation ... potential molecular diagnosis for 25 percent, including detection ... new mutations contributing to disease, according to a ... is being released to coincide with the American ... sequencing analyzes the exons or coding regions of ...
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... 28, 2011) University of Kentucky plant pathologists recently discovered ... the ability of plants, animals, humans and one-celled microorganisms to ... level, which is known as systemic immunity. This mode of ... the key events that stimulate that resistance have remained a ...
... Western Reserve University has detected tiny amounts of Iodine 131 ... campus building. Gerald Matisoff, professor of geology, said ... health. He estimated the level of radiation is about one-tenth ... 131 could have come from any radioactive waste processing facility," ...
... of scientists has discovered that descendants of "exploratory" butterflies ... cautious cousins. The team, led by James Marden, a ... Wheat, a post-doctoral scholar working at both Penn State ... the genetic bases for faster egg maturation, a higher ...
Cached Biology News:Kentucky researchers find a key to plant disease resistance 2Butterfly study reveals traits and genes associated with establishment of new populations 2Butterfly study reveals traits and genes associated with establishment of new populations 3Butterfly study reveals traits and genes associated with establishment of new populations 4
...
... High pH This pH 9.9 solution ... to immunohistochemical staining procedures. It is for ... on glass slides. For particular antigens, target ... effective. It should be noted that also ...
... A very potent Rnase ... effective over a broad range ... This protein does not inhibit ... polymerase, AMV and M-MLV reverse ...
... Dako Target Retrieval Solution, pH 9 (x ... buffer, pH 9, intended for heat-induced target ... is well-suited for use on formalin-fixed, paraffin-embedded ... with 0.01 mol/L citrate buffer, pH 6, ...
Biology Products: